How does variation in vision after treatment for nAMD affect QoL?
Research type
Research Study
Full title
FULL/LONG TITLE OF THE STUDY Variation in United Kingdom (UK) Neovascular Age Related Macular Degeneration (nAMD) outcomes: what effect do variations in visual outcomes have on quality of life? A prospective, observational cohort study.
IRAS ID
248323
Contact name
Claire Gill
Contact email
Sponsor organisation
University of York
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
The research question being addressed is how do variations in visual outcomes in patients with neovascular age-related macular degeneration (nAMD) being treated with anti-vascular endothelial growth factor (anti-VEGF) therapy affect quality of life? This question is of relevance and importance to patients and the public because although we know that there is variation in the visual outcomes of patients with nAMD being treated with anti-VEGF therapy, we do not know how this variation affects quality of life for these patients. The disease area being studied is nAMD. The therapy being studied is anti-VEGF, which will include Ranibizumab and Aflibercept, which is injected into the eye (intravitreally). Patients with nAMD being treated with anti-VEGF therapy, who have been receiving treatment for at least 3 months would be eligible for all parts of the study. The study will be conducted at the Ophthalmology Department at York Hospital. The study will last 18 months. Patients will be recruited to take part in a questionnaire study, with quality of life questionnaires being completed at baseline and 12 months.
REC name
London - Dulwich Research Ethics Committee
REC reference
18/LO/2082
Date of REC Opinion
11 Dec 2018
REC opinion
Further Information Favourable Opinion